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Purpose: To report the biochemical failure-free survival (BFFS), cause-speciﬁc survival (CSS), and overall
survival (OS) outcomes of patients treated with iodine-125 (I-125) brachytherapy for clinically localized
prostate cancer.
Methods and materials: Between 2003 and 2009, I-125 permanent prostate brachytherapy without supple-
mental external-beam radiotherapy was performed for 663 patients with low-risk and low-tier interme-
diate-risk (deﬁned as organ-conﬁned disease, PSA <10 ng/mL, and Gleason score 3 + 4with biopsy positive
core rate <33%) prostate cancer. Early in the study period, the preplanning method was used in the ﬁrst
104 patients, and later the real-time planningmethodwas used. Biochemical failurewas determined using
the American Society for Therapeutic Radiology Oncology (ASTRO) and Phoenix deﬁnitions.
Results: The 7-year BFFS rates for the ASTRO and Phoenix deﬁnitions were 96.1% and 95.9%, respectively.
The corresponding BFFS rates by risk group were 97.6% and 96.7% for low-risk, and 91.8% and 93.6% for
low-tier intermediate-risk disease (p = 0.007 and 0.08, respectively). Themedian times to biochemical fail-
ure in those who failed were 29.5 and 43.9 months according to the ASTRO and Phoenix deﬁnitions,
respectively. The 7-year CSS and OS were 99.1% and 96.4%. There was no signiﬁcant difference in CSS or
OS between the low-risk and low-tier intermediate-risk groups. In multivariate Cox regression analysis,
risk group and prostate D90 were independent predictors of BFFS for the ASTRO deﬁnition, while only
the prostate D90 was signiﬁcant for the Phoenix deﬁnition.
Conclusion: I-125 prostate brachytherapy results in excellent 7-year BFFS, CSS, and OS for low-risk and
low-tier intermediate-risk prostate cancer.
 2013 Elsevier Ireland Ltd. Radiotherapy and Oncology 109 (2013) 241–245 This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Permanent prostate brachytherapy is now an established
modality in the treatment of localized prostate cancer, with several
long-term studies demonstrating biochemical control rates similar
to those obtained by radical prostatectomy and external beam
radiation therapy (EBRT) [1–4]. Technical advances are regularly
reported, including the use of transrectal ultrasound guidance for
preplanned or intraoperatively planned implants. The concept of
delivering high radiation doses to the prostate while sparing nor-
mal tissues makes brachytherapy an attractive treatment option.
In the larger series from highly experienced institutions, the bio-
chemical failure-free survival (BFFS) rates range from 85% to 98%
for low-risk patients [5–11] undergoing brachytherapy and from
80% to 97% for intermediate-risk patients [6–12].Permanent prostate brachytherapy using iodine-125 (I-125)
seeds has grown rapidly in Japan since the establishment of guide-
lines for this treatment modality and revision of the dosimetric
regulations related to radiation hazards and safety in 2003. In this
report, we summarize the 7-year outcomes of our experience with
permanent prostate brachytherapy alone. To our knowledge, this is
the ﬁrst report presenting outcomes more than 5 years after per-
manent prostate brachytherapy in an Asian country.Materials and methods
Between 2003 and 2009, 663 Japanese patients with clinically
localized prostate cancer were treated with I-125 permanent pros-
tate brachytherapy at the National Hospital Organization Tokyo
Medical Center and National Hospital Organization Saitama Hospi-
tal. All patients underwent brachytherapy more than 3 years
before this analysis. Patients were classiﬁed into prognostic risk
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(NCCN; www.nccn.org). In general, low-risk and low-tier interme-
diate-risk (deﬁned as organ-conﬁned disease, prostate speciﬁc
antigen [PSA] <10 ng/mL, and Gleason score 3 + 4 with biopsy posi-
tive core rate <33%) patients received permanent prostate brachy-
therapy without supplemental external-beam radiotherapy. There
were no discrepancies in treatment policy between the National
Hospital Organization Tokyo Medical Center and National Hospital
Organization Saitama Hospital. Two hundred and ninety-ﬁve
patients (44.5%) received neoadjuvant androgen deprivation with
the aim of prostate volume reduction or a longer waiting time.
Because the Japanese national policy for patient discharge criteria
mandates that total seed activity be kept below 1300 MBq, patients
with prostate volumes >40 cc usually must undergo hormonal
therapy to downsize the prostate prior to implantation. None of
our present patients received adjuvant androgen deprivation.
The implant technique was previously described in detail
[13,14]. Early in the study period, the preplanning method was
used in the ﬁrst 104 patients, and from December 2004 onward,
the procedure was changed to the real-time planning method. All
procedures were conducted utilizing I-125 free seeds, being the
only approved radioisotope available for permanent prostate
brachytherapy in Japan. Post-implant dosimetry was performed
1 month after implantation, and the minimal dose received by
90% of the prostate (prostate D90) was the post-implant variable
analyzed.
Planned follow-up was by PSA blood tests and physical exami-
nation every 3 months for the ﬁrst 2 years, every 6 months there-
after. The primary outcome measure was BFFS. Biochemical
failure was determined using the American Society for Therapeutic
Radiology and Oncology (ASTRO) deﬁnition [15] and the nadir
+2 ng/mL deﬁnition (the Phoenix deﬁnition) [16]. Patients meeting
the criteria for biochemical failure but showing a subsequent
decrease to <0.5 ng/mL without intervention were classiﬁed as
having a benign bounce, and were excluded from the analysis of
failure. Late toxicity was deﬁned as any symptom developing after
the ﬁrst year, or symptoms that developed during the ﬁrst year and
persisted P12 months. Late toxicity was scored by the Common
Terminology Criteria for Adverse Events version 4.0.
Actuarial survival curves were calculated by the Kaplan–Meier
method to determine BFFS, cause-speciﬁc survival (CSS), and over-
all survival (OS), with differences between time-adjusted rates
evaluated with the log-rank test. Multivariate Cox regression anal-
ysis was used to assess the predictors of biochemical failure. Anal-Table 1
Clinical, treatment, and dosimetric parameters.
Low risk (n = 488) Low-tier inter
Median Range/count (%) Median
Continuous variables
Age (yr) 67.0 38–83 68.0
Initial PSA (ng/mL) 6.48 3.0–9.9 6.50
Positive biopsy rate (%) 20.0 5.0–100 21.0
Prostate volume (cc) 24.7 8.3–45.5 23.1
Prostate D90 (Gy) 182.7 128.9–228.3 184.2
Categorical variables
Clinical stage
T1c-2a 488 (100%)
T2b-2c 0
Neoadjuvant hormone therapy
Yes 222 (45.5%)
Planning technique
Preplanning 92 (18.9%)
Real-time planning 396 (81.1%)
Abbreviations: PSA = prostate speciﬁc antigen; D90 = the minimal dose received by 90% oyses were carried out using SPSS 20.0 (SPSS Inc., Chicago, IL). All
tests were two-sided, and statistical signiﬁcance was set at the
level of p < 0.05.Results
Clinical, treatment, and dosimetric parameters for the 663
patients included in the analysis are detailed in Table 1. Median
follow-up time was 60 (range, 6–101) months. In our study, in
655 patients (98.7%) with implants, prostate D90 was above
140 Gy. The median nadir PSA values among biochemically con-
trolled patients were 0.08 (range, <0.01–2.28) ng/mL for the entire
cohorts and 0.14 (range, <0.01–2.28) ng/mL for the neoadjuvant
hormone-naïve group, respectively.
The 7-year BFFS rate for the group overall was 96.1% according
to the ASTRO deﬁnition and 95.9% by the Phoenix deﬁnition. The
median times to biochemical failure in those who failed were
29.5 and 43.9 months according to the ASTRO and Phoenix deﬁni-
tions, respectively. The 7-year BFFS rates for low-risk and low-tier
intermediate-risk patients were 97.6%, and 91.8%, respectively
(p = 0.007) according to the ASTRO deﬁnition. The 7-year BFFS
rates for low-risk and low-tier intermediate-risk patients were
95.9%, and 93.6%, respectively, (p = 0.08) according to the Phoenix
deﬁnition (Fig. 1).
The 7-year CSS for the cohort overall was 99.1%. CSS stratiﬁed
by risk group was 98.9% for low-risk and 100% for low-tier inter-
mediate-risk disease (p = 0.43). The 7-year OS for the cohort overall
was 96.4%. OS stratiﬁed by risk group was 96.4% for low-risk and
96.5% for low-tier intermediate-risk disease (p = 0.87) (Fig. 2).
There were 19 deaths (2.9%), of which 2 were due to prostate
cancer.
Multivariate Cox regression analysis including age, PSA, Gleason
score, biopsy positive core rates, risk group, neoadjuvant hormone
administration, planning technique, and prostate D90 was con-
ducted to test for predictors of BFFS. Risk group and prostate D90
were independent predictors of BFFS by the ASTRO deﬁnition,
while only the prostate D90 was signiﬁcant by the Phoenix deﬁni-
tion (Table 2). The prostate D90 doses were divided into three
groups: <150 Gy (n = 25, 3.8%); 150–180 Gy (n = 271, 40.9%); and
>180 Gy (n = 367, 55.3%). As shown in Fig. 3, the 7-year BFFS rates
for patients in the prostate D90 >180 Gy group and the 150–180 Gy
group were 97.3% and 96.2%, respectively, compared with 81.5% for
those treated with D90 <150 Gy (p = 0.001), according to the Phoe-mediate risk (n = 175) p Value Total (n = 663)
Range/count (%) Median Range/count (%)
50–87 0.24 67.0 38–87
3.4–9.9 0.78 6.49 3.0–9.9
5.0–100 0.59 20.0 5.0–100
9.8–40.9 0.08 24.4 8.3–45.5
143.8–229.1 0.31 183.1 128.9–229.1
149 (85.1%) <0.01 637 (96.0%)
26 (14.9%) 26 (4.0%)
73 (41.7%) 0.22 295 (44.5%)
12 (6.9%) <0.01 104 (15.7%)
163 (93.1%) 559 (84.3%)
f the prostate.
T. Ohashi et al. / Radiotherapy and Oncology 109 (2013) 241–245 243nix deﬁnition. There was no signiﬁcant difference between the
prostate D90 >180 Gy and 150–180 Gy groups.
There were no advantages to using neoadjuvant androgen
deprivation in this patient population. As shown in Fig. 4, the 7-
year BFFS rates for patients receiving the prostate D90 P150 Gy
with neoadjuvant androgen deprivation was 96.9%, compared with
97.3% for those receiving the prostate D90 P150 Gy without neo-
adjuvant androgen deprivation (p = 0.67), according to the Phoenix
deﬁnition.
Late grade 2–3 gastrointestinal (GI) and genitourinary (GU) tox-
icity was experienced by 11 patients (1.7%) and 52 patients (7.8%),
respectively. Four patients (0.6%) experienced grade 3 GU toxicity.
No grade 3 or greater GI toxicity was observed. The late grade 2 GI
toxicities primarily related to rectal bleeding and the late grade 2–
3 GU toxicities consisted of urinary urgency or retention. Rectal or
urethral doses were not associated with the development of grade
2–3 GI or GU toxicity on univariate analysis. In 380 patients who
were potent before treatment, the actuarial potency preservation
rate was 48.0% at 3 years after brachytherapy. The prostate D90
was not associated with potency preservation at 3 years.Fig. 1. Freedom from biochemical failure using the Phoenix deﬁnition by risk
group.
Fig. 2. Overall survival by risk group.Discussion
Brachytherapy has become widely accepted for treating local-
ized prostate cancer with excellent and durable intermediate- to
long-term results being obtained in many centers [7,8,17,18].
There have been a variety of approaches including the use of pre-
planning vs. intraoperative planning, and loose vs. stranded seeds,
but all agree on the importance of quality implants. The impor-
tance of quality is reﬂected in the presence of a well-established
dose–response relationship [19–22]. Zelefsky et al. reported that
D90 >140 Gy on Day 0 of dosimetry signiﬁcantly impacted the bio-
chemical control rates in patients given I-125 monotherapy. The 5-
year BFFS rates for patients treated with monotherapy using D90
higher than 140 Gy was 99% vs. only 89% for those treated with
D90 lower than 140 Gy on Day 0 dosimetric evaluation [19]. In
our current study, in 655 patients (98.7%) with implants, prostate
D90 was above 140 Gy and the signiﬁcant dose threshold was
150 Gy. The timing of post-implant computed tomography (CT)
in our study was 1 month after seed implantation, and the prostate
D90 tended to be increased by approximately 10% on Day 30 CT as
compared with Days 0–1 CT due to resolution of prostate swelling
[14]. Therefore, our current results are considered to be consistent
with those reported by Zelefsky et al. [14].
Stock et al. [18] have identiﬁed the biologically effective dose
(BED) as being one method of equating different isotopes, doses,
and the addition of EBRT [18]. In analyzing the BED results of six
large and experienced brachytherapy centers, patients with low-
risk disease had an improved outcome with a BED P140 Gy [20].
Patients with a BED <140 Gy had a 10-year BFFS rate of 69.8%, as
compared to those with an intermediate dose (140–200 Gy) who
had a BFFS rate of 86% and those with a high dose (>200 Gy) who
had a BFFS rate of 88.1% by the ASTRO deﬁnition; that is, in the
low-risk group, it appeared that an insigniﬁcant difference exists
between the intermediate and high dose. In our dataset, even
though high quality of implant (prostate D90 >140 Gy) was
achieved in most patients, dose–response relationship was still
identiﬁed. The cut-off dose for dose–response was 150 Gy, but
there was no necessity for dose escalation beyond the Day 30
post-implant prostate D90 of 150 Gy (calculated BED, 157 Gy).
Although there are reports showing the feasibility, safety, and
oncologic results of the prostate D90 of 180 Gy or greater [9,23],
the need for a prostate D90 of 180 Gy or more was not established
in the low-risk or the low-tier intermediate-risk group.
Factors inﬂuencing selection of intermediate-risk patients trea-
ted with brachytherapy without supplemental EBRT included the
standard three risk factors for clinical tumor classiﬁcation, PSA
level, and Gleason score, along with the biopsy positive core rate
and the presence of perineural invasion on the biopsy specimen.
Various combinations of these factors were examined. It was found
that more than half of the practitioners would treat certain inter-
mediate-risk patients with monotherapy depending on the num-
ber and type of risk factors. The American Brachytherapy Society
recommends that intermediate-risk patients possibly be consid-
ered for monotherapy at the discretion of treating physicians
[24]. We used brachytherapy without supplemental EBRT for
selected low-tier intermediate-risk patients with organ-conﬁned
disease, PSA <10 ng/mL, and Gleason score 3 + 4 with biopsy posi-
tive core rate <33%. Even though the difference between the low-
risk and low-tier intermediate-risk groups was signiﬁcant by the
ASTRO deﬁnition, the difference was small and the outcome for
low-tier intermediate risk patients was sufﬁcient as compared
with the published outcomes of low-risk patients [17,25]. In a
recent series of 144 intermediate-risk patients given monotherapy
with detailed dosimetry available, the 12-year BFFS and CSS were
reportedly 96% and 100%, respectively [25]. Munro et al. examined
Table 2
Cox regression for biochemical failure according to the ASTRO deﬁnition and the Phoenix deﬁnition.
Variable ASTRO deﬁnition Phoenix deﬁnition
Signiﬁcance (p value) Hazard rate 95% CI Signiﬁcance (p value) Hazard rate 95% CI
Lower Upper Lower Upper
Age 0.393 0.973 0.915 1.036 0.538 0.979 0.913 1.049
Gleason score 0.730 1.189 0.445 3.174 0.527 1.406 0.489 4.043
Positive biopsy rate 0.305 1.324 0.775 2.263 0.114 1.551 0.899 2.673
Risk group 0.009 3.754 1.398 10.086 0.095 2.471 0.854 7.150
Neoadjuvant hormone therapy 0.825 0.890 0.317 2.503 0.454 0.659 0.221 1.963
Planning technique 0.372 0.537 0.137 2.102 0.501 0.617 0.151 2.520
Prostate D90 0.003 0.957 0.930 0.985 0.006 0.958 0.929 0.988
Abbreviations: CI = conﬁdential interval; prostate D90 = the minimal dose received by 90% of the prostate.
Fig. 3. Freedom from biochemical failure for the Phoenix deﬁnition according to the
prostate D90 dosimetric assessment.
Fig. 4. Freedom from biochemical failure for the Phoenix deﬁnition according to the
use of neoadjuvant androgen deprivation applying the prostate D90 P150 Gy
group.
244 Outcomes following I-125 prostate brachytherapya 10-year BFFS of 86.7% (ASTRO deﬁnition) and 82.1% (Phoenix def-
inition) for a cohort of T1c-2 Gleason score 3 + 4 prostate cancer
with a PSA610.0 ng/mL treated with I-125monotherapy [21]. Her-
bert et al. compared the outcome of 1500 patients with Gleason 7disease who underwent I-125 brachytherapy with 6 months
androgen deprivation and found no difference between primary
patterns 3 and 4 [12]. The RTOG clinical trial 0232 randomizes
men with intermediate-risk disease and only one adverse factor
to monotherapy or seed implantation combined with EBRT and
was close to accrual earlier in 2012.
With regard to androgen deprivation therapy, it is unnecessary
for low-risk prostate cancer except for the purpose of prostate vol-
ume reduction, or in the uncommon circumstance when other fac-
tors suggest more advanced disease than is immediately evident
such as high-volume disease in the biopsy specimen, or a rapidly
rising PSA [24]. Ash et al. have found that androgen deprivation
has no signiﬁcant impact on BFFS when given in association with
brachytherapy and that this is independent of the risk group
[26]. Castle et al. deﬁned a favorable intermediate-risk subset with
low Gleason score = 6 and less bulky (6T2b) disease or slightly
higher Gleason score (3 + 4) but minimal clinical disease (T1c),
and have found nearly identical BFFS whether treated with or
without androgen deprivation (BFFS at 5 years 94% vs. 95%, respec-
tively). This was further supported by multivariate analysis of this
favorable subset of patients for whom the use of androgen depriva-
tion was not found to be predictive of BFFS [27].
Several studies evaluating racial differences in biochemical dis-
ease recurrence among patients who received radiotherapy
obtained equivocal results. Yamoah et al. reported that the 10-year
BFFS rate was 90% for Caucasian and 76% for African American men
(p = 0.041) among those with low-risk disease, and that the 10-
year BFFS rate for patients who received brachytherapy alone
was 86% for Caucasian and 61% for African American men
(p = 0.001) [28]. Conversely, Lee et al. compared BFFS between
246 African American and 835 Caucasian men who received brach-
ytherapy with or without EBRT and/or hormone therapy for clini-
cally localized prostate cancer [29]. The authors concluded that
race was not a predictor of 5-year BFFS among patients in the
low-risk, intermediate-risk, and high-risk groups, regardless of
hormone therapy. This is the ﬁrst report presenting more than 5-
year outcomes of permanent prostate brachytherapy from an Asian
country. Our current results for Japanese men appear to be consis-
tent with those obtained for Caucasian men in the study by
Yamoah et al. [28].Conclusions
For Japanese patients with low-risk or low-tier intermediate
risk prostate cancer, brachytherapy alone is sufﬁcient to achieve
optimal biochemical control outcomes. We found no advantage
to using neoadjuvant hormone therapy in this patient population.
Our ﬁndings demonstrated a dose–response relationship based
on the post-implant dosimetric analysis for D90 of the prostate
but there was no apparent beneﬁt from high doses (>180 Gy).
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